Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3ITD AML with Secondary Acquired Mutations

被引：3

作者：

Yamatani, Kotoko ^{[1
]}

Tabe, Yoko ^{[2
,3
,4
]}

Saito, Kaori ^{[1
]}

Yang, Haeun ^{[1
,5
]}

Murakami-Tonami, Yuko ^{[1
]}

Suzuki, Koya ^{[1
,6
]}

Zhang, Weiguo ^{[7
]}

Kinjo, Sonoko ^{[8
]}

Ikeo, Kazuho ^{[8
]}

Mogushi, Kaoru ^{[9
,10
]}

Hosoya, Masaki ^{[10
,11
]}

Yamaguchi, Shigeo ^{[11
]}

Harada, Hironori ^{[12
]}

Miida, Takashi ^{[1
]}

Shah, Neil P. ^{[13
]}

Konopleva, Marina Y. ^{[14
]}

Hayashizaki, Yoshihide ^{[15
]}

Andreeff, Michael ^{[14
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Clin Lab Med, Tokyo, Japan

[2] Juntendo Univ, Dept Clin Lab Med, Sch Med, Tokyo, Japan

[3] Juntendo Univ, Grad Sch Medcine, Dept Next Generat Hematol Lab Med, Tokyo, Japan

[4] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[5] Juntendo Univ, Grad Sch Med, Leading Ctr Dev & Res Canc Med, Tokyo, Japan

[6] Juntendo Univ, Res Inst Dis Old Age, Grad Sch Med, Tokyo, Japan

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Natl Inst Genet, Ctr Informat Biol, Shizuoka, Japan

[9] Juntendo Univ, Grad Sch Med, Dept Diagnost & Therapeut Intractable Dis, Tokyo, Japan

[10] Juntendo Univ, Grad Sch Med, Intractable Dis Res Ctr, Tokyo, Japan

[11] Juntendo Univ, Sch Med, Dept Oncol, Tokyo, Japan

[12] Juntendo Univ, Grad Sch Med, Dept Hematol, Tokyo, Japan

[13] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Leukemia Biol Res, Houston, TX 77030 USA

[15] RIKEN, Ctr Life Sci Technoligies, Prevent Med & Diag Innovat Program, Yokohama, Kanagawa, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-109957

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3944

引用

页数：2

共 50 条

[41] Prognostic relevance of FLT3 mutations in AML
Blau, O.
Berenstein, R.
Sindarm, A.
Baldus, C. D.
Blau, I. W.
ONKOLOGIE, 2011, 34 : 77 - 77
[42] Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML
Zhang, Weiguo
Konopleva, Marina
Jacamo, Rodrigo O.
Borthakur, Gautam
Chen, Wenjing
Cortes, Jorge E.
Ravandi, Farhad
Andreeff, Michael
BLOOD, 2011, 118 (21) : 1495 - 1495
[43] Structural and numerical variation of FLT3/ITD in pediatric AML
Meshinchi, Soheil
Stirewalt, Derek L.
Alonzo, Todd A.
Boggon, Titus J.
Gerbing, Robert B.
Rocnik, Jennifer L.
Lange, Beverly J.
Gilliland, D. Gary
Radich, Jerald P.
BLOOD, 2008, 111 (10) : 4930 - 4933
[44] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
Wu, H.
Wang, A.
Qi, Z.
Li, X.
Chen, C.
Yu, K.
Zou, F.
Hu, C.
Wang, W.
Zhao, Z.
Wu, J.
Liu, J.
Liu, X.
Wang, L.
Wang, W.
Zhang, S.
Stone, R. M.
Galinsky, I. A.
Griffin, J. D.
Weinstock, D.
Christodoulou, A.
Wang, H.
Shen, Y.
Zhai, Z.
Weisberg, E. L.
Liu, J.
Liu, Q.
LEUKEMIA, 2016, 30 (10) : 2112 - 2116
[45] Inhibition of FLT3 in AML: a focus on sorafenib
Antar, A.
Otrock, Z. K.
El-Cheikh, J.
Kharfan-Dabaja, M. A.
Battipaglia, G.
Mahfouz, R.
Mohty, M.
Bazarbachi, A.
BONE MARROW TRANSPLANTATION, 2017, 52 (03) : 344 - 351
[46] Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth
Weir, Mark C.
Hellwig, Sabine
Tan, Li
Liu, Yao
Gray, Nathanael S.
Smithgall, Thomas E.
PLOS ONE, 2017, 12 (07):
[47] The growing landscape of FLT3 inhibition in AML
Smith, Catherine C.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 539 - 547
[48] Inhibition of FLT3 in AML: a focus on sorafenib
A Antar
Z K Otrock
J El-Cheikh
M A Kharfan-Dabaja
G Battipaglia
R Mahfouz
M Mohty
A Bazarbachi
Bone Marrow Transplantation, 2017, 52 : 344 - 351
[49] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
H Wu
A Wang
Z Qi
X Li
C Chen
K Yu
F Zou
C Hu
W Wang
Z Zhao
J Wu
J Liu
X Liu
L Wang
W Wang
S Zhang
R M Stone
I A Galinsky
J D Griffin
D Weinstock
A Christodoulou
H Wang
Y Shen
Z Zhai
E L Weisberg
J Liu
Q Liu
Leukemia, 2016, 30 : 2112 - 2116
[50] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Williams, A. B.
Nguyen, B.
Li, L.
Brown, P.
Levis, M.
Leahy, D.
Small, D.
LEUKEMIA, 2013, 27 (01) : 48 - 55

← 1 2 3 4 5 →